ticker
stringlengths 2
5
| disease
stringlengths 3
196
| stage
stringclasses 15
values | date
stringlengths 19
19
| catalyst
stringlengths 18
760
| label
int64 -1
1
|
|---|---|---|---|---|---|
BCAB
|
Solid Tumors
|
Phase 2
|
2023-01-10 00:00:00
|
Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled, noted January 10, 2023.
| 1 |
FREQ
|
Acquired Sensorineural Hearing Loss (SNHL)
|
Phase 2a
|
2021-03-23 00:00:00
|
Phase 2a trial did not show improvement versus placebo - March 23, 2021.
| 1 |
GILD
|
Refractory diffuse large B-cell lymphoma (DLBCL)
|
Approved
|
2022-04-01 00:00:00
|
Approved April 1, 2022.
| 1 |
MITO
|
Mitochondrial disease associated with pathogenic nDNA mutations (nPMD)
|
Phase 3
|
2019-12-20 00:00:00
|
Phase 3 data did not meet primary endpoint - December 20, 2019.
| 1 |
JNJ
|
Urothelial cancer
|
Approved
|
2019-04-12 00:00:00
|
FDA Approval announced April 12, 2019.
| 1 |
INVA
|
Asthma
|
Approved
|
2020-09-09 00:00:00
|
FDA approval announced September 9, 2020.
| 1 |
JNJ
|
Treatment resistant depression
|
Approved
|
2019-03-05 00:00:00
|
FDA approval announced March 5, 2019.
| 1 |
VTGN
|
Major depressive disorder (MDD)
|
Phase 1
|
2023-06-21 00:00:00
|
Phase 1 study results showed that dosing was well-tolerated and demonstrated a favorable safety and tolerability profile across single and multiple dose intranasal administrations, noted June 21, 2023.
| 1 |
ALPN
|
Lupus nephritis, IgA nephropathy
|
Phase 1/2
|
2023-11-02 00:00:00
|
Phase 1b/2a data presented at ASN reported that treatment reduced UPCR by greater than 50% in IgA nephropathy, noted November 2, 2023.
| 1 |
AQST
|
Allergic reactions (anaphylaxis)
|
Phase 2
|
2023-02-24 00:00:00
|
Phase 2 pharmacokinetic and pharmacodynamic data due presented at AAAAI reported rapid absorption following sublingual administration with the fastest observed median Tmax (12 min forAQST-109, 23 min for EpiPen, and 45 min for IM injection), noted February 24, 2023.
| 1 |
ALNY
|
Hereditary transthyretin-mediated (hATTR) amyloidosis
|
Approved
|
2022-06-14 00:00:00
|
Approved June 14, 2022.
| 1 |
NVS
|
Pegfilgrastim biosimilar
|
Approved
|
2019-11-05 00:00:00
|
FDA Approval announced November 5, 2019.
| 1 |
SLRN
|
Hidradenitis Suppurativa (HS)
|
Phase 2/3
|
2023-09-11 00:00:00
|
Phase 2b/3 data to did not meet statistical significance at week 16, noted Septemeber 11, 2023.
| 1 |
MGTX
|
X-linked retinitis pigmentosa (XLRP)
|
Phase 1/2
|
2022-10-01 00:00:00
|
Full Phase 1/2 data presented at AAO reported an improvement in mean retinal sensitivity in the treated eye compared to untreated eyes in the randomized concurrent control arm, noted October 1, 2022.
| 1 |
NVS
|
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
|
Phase 3
|
2023-09-25 00:00:00
|
Phase 3 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR), noted September 25, 2023.
| 1 |
VERU
|
COVID-19 / Severe Acute Respiratory Syndrome, SARS-CoV-2, Influenza A and B, Respiratory Syncytial Virus (RSV) and other viruses
|
Phase 3
|
2023-09-26 00:00:00
|
Phase 3 new study authorized by FDA, with an FDA meeting in September 2023 resulted in agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication, noted September 26, 2023.
| 1 |
TNXP
|
Post-traumatic stress disorder (PTSD)
|
Phase 3
|
2020-12-21 00:00:00
|
Phase 3 primary endpoint was not met - December 21, 2020.
| 0 |
IPHA
|
Solid tumors
|
Phase 1
|
2022-12-09 00:00:00
|
Phase 1 data reported that IPH5201 blocks ATP degradation and blocks CD39-mediated degradation of eATP released after chemotherapy treatment, noted December 8, 2022.
| 1 |
BLUE
|
Relapsed/refractory multiple myeloma
|
Approved
|
2021-03-26 00:00:00
|
FDA approval announced March 26, 2021.
| 1 |
ARDX
|
Serum phosphorus - chronic kidney disease (CKD) on dialysis
|
Approved
|
2023-10-17 00:00:00
|
Approved October 17, 2023.
| 1 |
GTHX
|
Second/third-line treatment of NSCLC
|
Phase 2
|
2021-11-03 00:00:00
|
Phase 2 trial discontinued, noted November 3, 2021.
| -1 |
LCTX
|
Non-small cell lung cancer (NSCLC)
|
Phase 1
|
2023-07-24 00:00:00
|
Phase 1 data reported that five of eight patients treated (62.5%) had a best response of immune-related stable disease, and three (37.5%) demonstrated immune-related progressive disease, noted July 24, 2023.
| 1 |
CRNX
|
Congenital adrenal hyperplasia and Cushing’s disease
|
Phase 1
|
2022-05-25 00:00:00
|
Data from MAD cohort results showed serum cortisol below normal levels and a marked reduction in 24-hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations, noted May 25, 2022.
| 1 |
ALBO
|
Alagille syndrome (ALGS)
|
Approved
|
2023-06-13 00:00:00
|
FDA Approved on June 13, 2023.
| 1 |
XERS
|
Endogenous Cushing’s syndrome
|
Phase 3
|
2022-05-12 00:00:00
|
Phase 3 presentation of data at AACE reported that mean total and LDL cholesterol levels were significantly increased with placebo versus treatment, noted May 12, 2022.
| 1 |
BDTX
|
Glioblastoma multiforme (GBM) and NSCLC
|
Phase 1
|
2023-10-14 00:00:00
|
Phase 1 clinical data presented at AACR-NCI-EORTC meeting reported that five of the 13 patients with either intrinsic driver, acquired resistance or complex mutations had a confirmed partial response (PR), noted October 14, 2023.
| 1 |
RHHBY
|
Neuromyelitis optica spectrum disorder (NMOSD)
|
Approved
|
2020-08-14 00:00:00
|
FDA approval announced August 14, 2020.
| 1 |
VTRS
|
Dry eye disease
|
Approved
|
2022-02-03 00:00:00
|
Approved February 3, 2022.
| 1 |
ABBV
|
Facial Erythema (Redness) Associated with Rosacea
|
Approved
|
2017-01-19 00:00:00
|
Approved January 19, 2017.
| 1 |
PFE
|
Acute treatment of migraine
|
Approved
|
2020-02-27 00:00:00
|
FDA Approval announced February 27, 2020.
| 1 |
SAGE
|
Major depressive disorder (MDD)
|
CRL
|
2023-08-04 00:00:00
|
CRL issued August 4, 2023.
| 0 |
AMGN
|
Immune Thrombocytopenia (Pediatric)
|
Approved
|
2018-12-14 00:00:00
|
FDA approval announced December 14, 2018.
| 1 |
STRO
|
Relapsed/refractory AML
|
Phase 1
|
2022-12-12 00:00:00
|
Phase 1 data presented at ASH reported that treatment was well-tolerated with 47% of the patients achieved complete remission and 53% of the patients achieved partial response or stable disease, noted December 12, 2022.
| 1 |
FULC
|
COVID-19
|
Phase 3
|
2021-03-04 00:00:00
|
Phase 3 trial to be discontinued - March 4, 2021.
| -1 |
QURE
|
Hemophilia B
|
Approved
|
2022-11-22 00:00:00
|
Approved November 22, 2022.
| 1 |
PFE
|
Hemophilia A or B
|
Phase 3
|
2023-11-02 00:00:00
|
Phase 3 data from ASH abstract reported that OD group reported 12 (36.4%) adverse events (AEs) during ATP vs 9 (24.3%) in OP whereas the RP group reported 62 (74.7%) AEs in ATP vs 20 (22.0%) in OP, noted November 2, 2023.
| 0 |
NBIX
|
Tardive dyskinesia (TD)
|
Phase 3
|
2023-08-29 00:00:00
|
Phase 3 data reported that the mean AIMS total score at baseline was 14.6 and decreased over 48 weeks, with a mean change from baseline of -10.2 , noted August 29, 2023.
| 0 |
NKTR
|
Systemic lupus erythematosus (SLE)
|
Phase 2
|
2023-04-27 00:00:00
|
Phase 2 to be moved to from Lupus to Atopic dermatitis after disappointing results, noted April 27, 2023.
| 0 |
KNSA
|
Giant cell arteritis (GCA)
|
Phase 2
|
2020-10-06 00:00:00
|
Phase 2 trial met endpoints - October 6, 2020.
| 0 |
PRVB
|
Coxsackievirus B (CVB) vaccine
|
Phase 1
|
2021-10-26 00:00:00
|
Phase 1 interim data met the primary endpoint and secondary efficacy endpoint as it induced high titers of viral-neutralizing antibodies against all CVB serotypes, noted October 26, 2021.
| 0 |
ERAS
|
Advanced solid tumors
|
Phase 1b
|
2023-04-18 00:00:00
|
Phase 1b data presented at AACR showed that dosing was well-tolerated with favorable pharmacokinetics and no apparent drug-drug interactions, noted April 18, 2023.
| 1 |
JNJ
|
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
|
Approved
|
2020-04-21 00:00:00
|
FDA Approval announced April 21, 2020.
| 1 |
ARQT
|
Plaque psoriasis
|
Phase 3
|
2022-03-25 00:00:00
|
Phase 3 pooled data reported that 40% of patients treated with roflumilast cream achieved IGA success and and 48% of patients treated with roflumilast cream achieved IGA status of clear, noted March 25, 2022.
| 1 |
HCM
|
Intrahepatic cholangiocarcinoma (IHCC)
|
Phase 2
|
2023-05-25 00:00:00
|
Phase 2 first in human data reported that the best overall response by investigator assessment was confirmed partial response in seven (31.8%) pts and stable disease in an additional 12 pts, noted May 25, 2023.
| 0 |
ALPMY
|
Nonmetastatic Prostate Cancer (nmCSPC)
|
Phase 3
|
2023-05-01 00:00:00
|
Additional Phase 3 data reported that treatment reduced the risk of metastasis or death by 58% versus placebo plus leuprolide, noted May 1, 202
| 1 |
ALXO
|
Head and neck squamous cell carcinoma (HNSCC)
|
Phase 2
|
2021-11-09 00:00:00
|
Phase 2 clinical data showed that patients with 1L HNSCC who have not received prior treatment for their advanced disease (n=13), the dose demonstrates an initial ORR of 38.5% with a 12-month OS rate of 87.5% and mOS not reached in combination with pembrolizumab + 5FU + platinum. These results compare favorably with benchmark survival data from standard pembrolizumab + chemotherapy, noted November 9, 2021.
| 1 |
EGRX
|
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
|
CRL
|
2016-03-18 00:00:00
|
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product.
| 0 |
AZN
|
Type 2 diabetes (Pediatric)
|
Approved
|
2021-07-23 00:00:00
|
FDA approval announced July 23, 2021.
| 1 |
KNSA
|
COVID-19
|
Phase 2
|
2020-12-22 00:00:00
|
Phase 2 trial did not meet primary endpoint - December 22, 2020.
| 1 |
BMY
|
Non-Small Cell Lung Cancer (NSCLC)
|
Phase 3
|
2022-04-11 00:00:00
|
Phase 3 results reported that treatment reduced the risk of disease recurrence, progression or death by 37%, noted April 11, 2022.
| 1 |
ACIU
|
Alzheimer’s disease (AD)
|
Phase 2
|
2022-12-01 00:00:00
|
Phase 2 pharmacodynamic effects data presented at CTAD on December 1, 2022.
| 1 |
GLPG
|
Ankylosing spondylitis
|
Phase 2
|
2018-09-05 00:00:00
|
Phase 2 data released September 6, 2018. Primary endpoint met.
| 0 |
REGN
|
Non-small cell lung cancer (NSCLC)
|
Phase 3
|
2021-09-19 00:00:00
|
Phase 3 data presented at ESMO September 19, 2021 showed trial met primary and all secondary endpoints, with an objective response rate of 43%.
| 1 |
MRKR
|
Acute Myeloid Leukemia (AML)
|
Phase 2
|
2022-02-16 00:00:00
|
Phase 2 data reported that one MRD positive patient converted to MRD negative following treatment, with no reported dose limiting toxicities, noted February 16, 2022.
| 1 |
OPK
|
Obesity and diabetes
|
Phase 2b
|
2019-03-21 00:00:00
|
Phase 2b top-line data March 21, 2019 met primary endpoint.
| 0 |
MRK
|
Renal cell carcinoma (RCC)
|
Approved
|
2021-11-18 00:00:00
|
Approved November 18, 2021.
| 1 |
PGEN
|
Ovarian cancer
|
Phase 1
|
2023-06-05 00:00:00
|
Phase 1 data presented at ASCO demonstrated expansion and persistence when delivered via either intraperitoneal or intravenous infusion without lymphodepletion or via intravenous infusion after lymphodepletion demonstrating the effectiveness of mbIL15, noted June 5, 2023.
| 1 |
BIIB
|
CKD Patients at Risk of Rapid Progression
|
Phase 2
|
2023-05-10 00:00:00
|
Program discontinued, noted May 10, 2023.
| -1 |
LLY
|
Heart failure with reduced ejection fraction
|
Approved
|
2021-08-18 00:00:00
|
FDA approval announced August 18, 2021.
| 1 |
PFE
|
Claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
|
Phase 3
|
2023-10-21 00:00:00
|
Phase 3 data presented at ESMO reported that median PFS was 11.0 vs 8.9 mo and median OS was 18.2 vs 15.6 mo, noted October 21, 2023.
| 1 |
ARWR
|
Alpha-1 Liver Disease
|
Phase 2
|
2023-06-24 00:00:00
|
Phase 2 data presented at EASL showed that at week 48, patients receiving 25, 100, or 200 mg fazirsiran achieved serum Z-AAT reductions of 74%, 89%, and 94%, respectively, versus an increase of 9% observed in patients receiving placebo, noted June 24, 2023.
| 1 |
CYDY
|
COVID-19 (Mild to Moderate)
|
Phase 2
|
2020-08-11 00:00:00
|
Phase 2 data released August 11, 2020 did not report primary endpoint data (TCSS at Day 14). Day 3 subgroup showed clinical improvement but not mentioned to be statistically significant. primary endpoint data for ALL treated patients NOT released. Secondary NEWS2 was met. No data on other secondary endpoints.
| 1 |
MGTA
|
Acute myeloid leukemia and myelodysplasia-excess blasts
|
Phase 1/2
|
2023-01-25 00:00:00
|
Company voluntarily paused trial after a Grade 5 Serious Adverse Event (SAE) (respiratory failure and cardiac arrest resulting in death of patient), noted January 25, 2023.
| -1 |
BIOR
|
Ulcerative Colitis (UC)
|
Phase 1a
|
2023-09-25 00:00:00
|
IND submitted to FDA, noted September 25, 2023.
| 0 |
SAVA
|
Mild-to-Moderate Alzheimer's Disease
|
Phase 3
|
2023-10-25 00:00:00
|
Phase 3 MRI data suggested that simufilam is not associated with treatment-emergent amyloid-related imaging abnormalities, or ARIA. MRIs were all analyzed for ARIA by board-certified neuroradiologists, noted October 25, 2023.
| 1 |
AZN
|
Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS)
|
Phase 3
|
2020-06-24 00:00:00
|
Phase 3 trial met primary endpoint - June 24, 2020
| 0 |
GSK
|
Cancer - ovarian
|
Approved
|
2017-03-27 00:00:00
|
PDUFA date under priority review was June 30, 2017. Approved March 27, 2017.
| 1 |
CTXR
|
Hemorrhoids
|
Phase 2b
|
2023-06-20 00:00:00
|
Phase 2b enrollment completed, noted April 3, 2023. Phase 2b data provided meaningful reduction in symptom severity when compared to individual components alone, noted June 20, 2023.
| 1 |
KPRX
|
Later-stage Retinitis Pigmentosa
|
Phase 2
|
2023-04-27 00:00:00
|
Phase 2 interim results presented at ARVO reported patient-reported improvement in the ability to perceive a contrast between light and dark at days seven 14 and 29, noted April 27, 2023.
| 1 |
BMY
|
Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia
|
Approved
|
2017-11-10 00:00:00
|
Approval announced November 10, 2017.
| 1 |
NBTX
|
Pancreatic cancer
|
Phase 1
|
2023-09-28 00:00:00
|
Phase 1 data reported a 92.3% local disease control rate (12/13) and a median Overall Survival of 21 months, noted September 28, 2023.
| 0 |
CALT
|
Alport Syndrome
|
Phase 2
|
2023-09-27 00:00:00
|
Phase 2 to be intiated in 4Q 2023. FDA granted Orphan Drug Designation, noted September 27, 2023.
| 0 |
AFMD
|
EGFR-expressing solid tumors
|
Phase 1/2
|
2023-06-03 00:00:00
|
Phase 1/2 interim data presented at ASCO reported that 7 out of 15 heavily pre-treated patients with tumor reductions, including 2 confirmed partial responses and 5 patients exhibiting stable disease, noted June 3, 2023.
| 1 |
SLRX
|
Hematological cancers and solid tumors
|
Phase 1
|
2023-06-12 00:00:00
|
Phase 1 clinical trial data revealed that in Jeko-1 (lymphoma) cells, SP-3164 induces twice the degradation of target proteins I/A at 1/10th the dose of lenalidomide, providing further support for the development of SP-3164 in relapsed refractory non-Hodgkin lymphoma, noted June 12, 2023.
| 0 |
BMY
|
Chronic Lymphocytic Leukemia (CLL)
|
Phase 1/2
|
2023-01-26 00:00:00
|
Phase 1/2 study met the primary endpoint of complete response rate compared to historical control in the prespecified subset of patients, noted January 26, 2023.
| 0 |
TTNP
|
Opioid dependence
|
Approved
|
2016-05-26 00:00:00
|
CRL issued April 30, 2013. Approved May 26, 2016.
| 1 |
PRTA
|
Psoriatic Arthritis
|
Phase 1b
|
2017-09-28 00:00:00
|
Phase 1b data released September 28, 2017 - insufficient meaningful clinical effect for further development.
| -1 |
FULC
|
Sickle Cell Disease
|
Phase 1
|
2023-02-24 00:00:00
|
IND placed on hold February 24, 2023.
| 0 |
LNTH
|
Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA)
|
Phase 3
|
2018-09-12 00:00:00
|
Phase 3 trial met one of two co-primary endpoints.
| 0 |
GANX
|
Parkinson's Disease
|
Phase 1
|
2023-10-04 00:00:00
|
Phase 1 trial dosing commenced, noted October 4, 2023.
| 0 |
GILD
|
Refractory Large B-cell Lymphoma (R-LBCL)
|
Phase 2
|
2022-06-06 00:00:00
|
Phase 2 data presented at ASCO reported a CR rate of 65% and ORR of 88%. With a median follow-up of 17 mo, 65% of the patients had ongoing response, with 57% ongoing in CR, noted June 6, 2022.
| 1 |
ACST
|
Hypertriglyceridemia
|
Phase 3
|
2020-08-31 00:00:00
|
TRILOGY 2 data August 31, 2020 also did not meet primary endpoint.
| 1 |
REGN
|
Homozygous familial hypercholesterolemia (HoFH)
|
Approved
|
2021-04-01 00:00:00
|
FDA approval announced April 1, 2021.
| 1 |
TVTX
|
Pantothenate kinase-associated neurodegeneration (PKAN)
|
Phase 3
|
2019-08-22 00:00:00
|
Phase 3 top-line data did not meet endpoints - August 22, 2019.
| 1 |
AXLA
|
Long COVID-19
|
Phase 2a
|
2023-04-17 00:00:00
|
Phase 2a data reported that fatigue responders showed significantly greater improvement in phosphocreatine recovery time, a marker of mitochondrial function, and a trend towards reductions in plasma FGF-21 and serum lactate at day 28 compared with placebo-treated patients, noted April 17, 2023.
| 1 |
SLNO
|
Prader-Willi syndrome (PWS)
|
Phase 3
|
2021-09-08 00:00:00
|
Phase 3 extension study data showed mean (SE) improvement in hyperphagia by a decrease in the HQ-CT total score, of -9.9 (0.77), was highly significant (p<0.0001) after receiving DCCR for 52 weeks, noted September 8, 2021.
| 1 |
URGN
|
Non-Muscle-Invasive Bladder Cancer
|
Phase 3
|
2023-07-27 00:00:00
|
Phase 3 trial met primary endpoint, noted July 27, 2023.
| 0 |
MBIO
|
X-linked Severe Combined Immunodeficiency (XSCID) - newly diagnosed infants
|
Phase 1/2
|
2019-04-17 00:00:00
|
Phase 1/2 trial ongoing. Initial data noted in NEJM.
| 0 |
BCYC
|
Solid tumors
|
Phase 1/2
|
2023-02-14 00:00:00
|
Phase 1/2 data reported a 50% ORR and 75% benefit rate, including one complete response, noted February 14, 2023.
| 0 |
AZN
|
Amyloidosis
|
Phase 2
|
2022-12-12 00:00:00
|
Phase 2 1-year study results reported that treatment has been generally well tolerated without evidence of organ toxicity. Organ response persisted even after cessation of anti-PCD treatment, noted December 12, 2022.
| 1 |
ERYP
|
Triple-Negative Breast Cancer (TNBC)
|
Phase 2
|
2022-09-19 00:00:00
|
Phase 2 data reported that no clinical benefit was demonstrated, noted September 19, 2022.
| 1 |
TNYA
|
Heart Failure with Preserved Ejection Fraction
|
Phase 1
|
2023-10-09 00:00:00
|
Phase 1 data presented at HFSA demonstrated safety and tolerability in healthy participants with dose-proportional pharmacokinetics and robust target engagement, noted October 9, 2023.
| 1 |
BMY
|
Stage IIB or IIC melanoma
|
Approved
|
2023-10-16 00:00:00
|
Approved October 13, 2023.
| 1 |
AYLA
|
Adenoid cystic carcinoma
|
Phase 2
|
2022-06-06 00:00:00
|
Phase 2 results reported an overall disease control rate of 69%, 14.6% in the 4mg group achieved a partial response, 8.3% in the 6 mg group, noted June 6, 2022.
| 1 |
MRK
|
High-Risk, Early-Stage ER+/HER2- Breast Cancer
|
Phase 3
|
2023-10-20 00:00:00
|
Phase 3 data presented at ESMO reported that treatment significantly improved pCR rate compared to neoadjuvant placebo plus chemotherapy (24.3% vs. 15.6%, respectively), noted October 20, 2023.
| 1 |
CHRS
|
Nasopharyngeal carcinoma (NPC)
|
Approved
|
2023-10-27 00:00:00
|
FDA Approval on October 27, 202
| 1 |
ACRS
|
Common warts (verruca vulgaris)
|
Phase 2
|
2019-10-24 00:00:00
|
Phase 3 data met all endpoints - second Phase 3 trial.
| 0 |
NVS
|
First-line use in patients with ALK+ metastatic NSCLC
|
Approved
|
2017-05-26 00:00:00
|
Priority review granted February 22, 2017. Approval announced May 26, 2017.
| 1 |
RHHBY
|
Diffuse Large B-Cell Lymphoma
|
BLA Filing
|
2023-03-10 00:00:00
|
Advisory committee meeting voted 11 to 2 in favor of approval, noted March 10, 2023.
| 1 |
VCEL
|
Focal chondral cartilage defects in the knee.
|
Approved
|
2016-12-13 00:00:00
|
FDA Approval announced December 13, 2016 ahead of PDUFA date of January 3 2017.
| 1 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.